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a b s t r a c t
Introduction: The aim of this study is to analyze the safety and efficacy of stent-graft
endovascular treatment for visceral artery aneurysms and pseudoaneurysms.
Methods: Multicentric retrospective series of patients with visceral aneurysms and pseu-
doaneurysms treated by means of stent graft. The following variables were analyzed: Age,
sex, type of lesion (aneurysms/pseudoaneurysms), localization, rate of success, intrapro-
cedural and long term complication rate (SIR classification). Follow-up was performed under
clinical and radiological assessment.
Results: Twenty-five patients (16 men), with a mean age of 59 (range 27–79), were treated.
The indication was aneurysm in 19 patients and pseudoaneurysms in 6. The localizations
were: splenic artery (12), hepatic artery (5), renal artery (4), celiac trunk (3) and gastroduo-
denal artery (1). Successful treatment rate was 96% (24/25 patients). Intraprocedural com-
plication rate was 12% (4% major; 8% minor). Complete occlusion was demonstrated during
follow up (mean 33 months, range 6–72) in the 24 patients with technical success. Two stent
migrations (2/24; 8%) and 4 stent thrombosis (4/24; 16%) were detected. Mortality rate
was 0%.
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Conclusion: In our study, stent-graft endovascular treatment of visceral aneurysmns and
pseudoaneurysms has demonstrated to be safe and is effective in the long-term in both
elective and emergent cases, with a high rate of successful treatment and a low complica-
tion rate.
# 2017 AEC. Published by Elsevier Espan˜a, S.L.U. All rights reserved.
Tratamiento endovascular de aneurismas y pseudoaneurismas de
arterias viscerales mediante stents recubiertos: ana´lisis de resultados
inmediatos y a largo plazo
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r e s u m e n
Introduccio´n: El objetivo de este estudio fue analizar la eficacia y la seguridad del tratamiento
de los aneurismas y pseudoaneurismas de arterias viscerales mediante la utilizacio´n de
stenstents recubiertos.
Metodos: Serie retrospectiva multice´ntrica de pacientes intervenidos por aneurisma o pseu-
doaneurisma mediante stents recubiertos. Las variables estudiadas fueron: edad, sexo, tipo
de lesio´n (aneurisma/pseudoaneurisma), localizacio´n, tasa de e´xito terape´utico, tasa de
complicaciones durante el procedimiento (segu´ n la clasificacio´n SIR) y en el seguimiento. El
seguimiento fue realizado mediante evaluacio´n clı´nica y radiolo´gica.
Resultados: Se trato´ a 25 pacientes (16 hombres) con una edad media de 59 an˜os (rango 27-79).
Diecinueve pacientes presentaban aneurismas y los restantes 6, pseudoaneurismas; la
localizacio´n principal fue la arteria esple´nica (12) seguida por las arterias hepa´tica (5), renal
(4), tronco celiaco (3) y gastroduodenal (1). La tasa de e´xito fue del 96% (24/25 pacientes). Las
complicaciones intraprocedimiento fueron del 12% (4% mayores; 8% menores). El tiempo
medio de seguimiento fue de 33 meses (rango 6-72 meses) en los 24 pacientes con e´xito
te´cnico, con oclusio´n completa del aneurisma en todos los casos. En el seguimiento se
observaron 2 casos de migracio´n (2/24; 8%) y 4 de trombosis del dispositivo (4/24; 16%); en
ninguno de estos pacientes se produjo dan˜o isque´mico del o´rgano. La mortalidad debida al
procedimiento fue del 0%.
Conclusiones: En nuestro estudio, el tratamiento endovascular de los aneurismas y pseu-
doaneurismas viscerales mediante stents recubiertos demuestra ser seguro y eficaz a largo
plazo, tanto de forma electiva como en urgencia, con una alta tasa de e´xito terape´utico y una
baja tasa de complicaciones.
# 2017 AEC. Publicado por Elsevier Espan˜a, S.L.U. Todos los derechos reservados.
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Visceral artery aneurysms are saccular or spindle-shaped
dilatations in the celiac trunk and its branches, superior or
inferior mesenteric arteries and renal arteries. They are
classically subdivided into false (also called pseudoa-
neurysms) and true. The walls of true aneurysms consist of
the 3 layers of the arterial wall and, in general, are considered
as such in the presence of a focal dilatation of the vessel
greater than 1.5 times the caliber of the healthy segment of the
affected vessel.1 The prevalence of true aneurysms in the adult
population is estimated at around 0.1%–2%,1 while the
incidence of pseudoaneurysms is difficult to calculate. True
aneurysms can occur as a result of an underlying arterial
disease, such as atherosclerosis, fibromuscular dysplasia, and
arteritis, and generally remain asymptomatic. False
aneurysms are ruptures of the arterial wall that are contained
between the adventitia or the perivascular tissues.1,2 Pseu-
doaneurysms are usually the result of direct trauma, inflam-
mation, or wall infection. In recent years, we have witnessedan increase in the diagnosis of aneurysmal disease as a result
of the greater demand for imaging tests (increasingly better
spatio-temporal resolution) and a surge in percutaneous,
laparoscopic and endoscopic procedures in the urinary and
biliary tracts, which increase the incidence of pseudoa-
neurysms.3
The most common site of aneurysms and pseudoa-
neurysms is the splenic artery and its branches (45%–70% of
cases),1,4,5 followed by a smaller percentage in the hepatic
artery (approximately 19%–20% of cases),4,6,7 renal artery
(15%–25%),1,4,8 and celiac trunk (4%–5%).1,4,9 Finally, the least
frequently involved vessels are the superior mesenteric,
gastroduodenal and pancreatic arteries.
The greatest complication of visceral aneurysms is rupture,
which can occur in approximately 20% of cases of true
aneurysms and in 70% of pseudoaneurysms, which results in
an associated mortality ranging from 25% to 100%.10–12 The
main indication for the treatment of visceral aneurysms is
size: those larger than 2 cm generally require treatment,
regardless of the location, whereas in smaller ones a watch-
and-wait approach is suitable, with follow-up imagingCIRENG-1767; No. of Pages 10
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therapeutic management are: the presence of associated
symptoms,15 the growth of more than 0.5 cm per year,16
pregnancy (maternal and fetal mortality in case of rupture is
higher),14,17 and the presence of certain associated systemic
vasculopathies (e.g., type IV Ehlers–Danlos).18 Location also
seems to influence the risk of rupture: aneurysms of the
hepatic artery, pancreatic arteries and superior mesenteric
artery are most related with rupture.19,20 Regarding pseudoa-
neurysms, there is broad consensus in the literature about the
need for treatment, regardless of location and size, due to the
high risk of rupture.18,21,22 However, in the pediatric popula-
tion or in some cases of adults with pseudoaneurysms less
than 5 mm in size, active follow-up with imaging techniques
has been preferred, providing resolution of the disease
without the need for invasive treatment.23,24
For many years, conventional surgical treatment has been
considered the treatment of choice for this entity, with
morbidity and mortality in elective cases of 1.3%–5% in the
case of aneurysms2,14,25 and 9.4%25 in pseudoaneurysms. In
urgent treatments, mortality varied depending on the loca-
tion, reaching 25% in the splenic artery and up to 100% in the
celiac trunk.2,13,26,27 In recent years, thanks to the important
advances in endovascular techniques, a range of possibilities
has been created for the minimally invasive treatment of
visceral aneurysms: embolization with metallic coils, injection
of liquid embolic agents (such as thrombin, N-butyl cya-
noacrylate [NBCA] or ethylene vinyl alcohol dissolved in
dimethyl sulfoxide), gelfoam (Pfizer, Puurs, Belgium), stents
(coated or uncoated combined with coils), plugs or vascular
occlusion devices such as the Amplatzer Vascular Plug (St.
Jude Medical, St. Paul, Minnesota, USA) or the Micro Vascular
Plug (Covidien, Irvine, California, USA), or the combination of
two or more of these techniques. In cases where there is no
surgical indication (either due to patient characteristics, or
because the treatment of the aneurysm or pseudoaneurysm
and its cause is not feasible), endovascular treatment is the
treatment of choice. Of these, the most frequently chosen
involves occlusion of the pathological vessel with coils. This
treatment has proven to be safe and effective, although it is at
the expense of sacrificing the treated vessel. The placement of
coated stents is an alternative that allows potentially
preserving vascular permeability and, therefore, distal perfu-
sion, while excluding vascular dilatation.
There are few papers published in the medical literature
about the endovascular treatment of visceral aneurysms
and pseudoaneurysms using coated stents.12,28,29 Our
objective is to analyze the long-term safety and efficacy
of the treatment of visceral aneurysms and pseudoa-
neurysms with coated stents by means of a multicenter
retrospective analysis.
Methods
We conducted a retrospective multicenter analysis of the
cases collected in databases with prospective patient intro-
duction from February 2006 to October 2015. Patients included
had visceral aneurysms (larger than 2 cm) or visceral
pseudoaneurysms of any size (including splenic, hepatic,renal, gastroduodenal, mesenteric and celiac arteries) treated
endovascularly with coated stent placement.
Informed consent was obtained for the procedure in all
patients. At the main medical center of this study, the Ethics
Committee did not require authorization for retrospective
studies. At both hospitals, informed consent included the
approval of patients to anonymously utilize their clinical data
for research and teaching purposes, in accordance with the
provisions of the corresponding Spanish Personal Data
Protection Law.
For each patient, the following variables were collected:
age, sex, type of vascular lesion (aneurysm or pseudoa-
neurysm), location of the lesion (hepatic, splenic, gastric,
celiac, superior mesenteric, gastroduodenal or renal artery)
and symptoms at presentation (incidental, hemorrhage,
abdominal pain).
The pseudoaneurysms differed from true aneurysms in
their clinical criteria (history of vessel trauma, bile duct
manipulations, inflammatory state or retroperitoneal or
intraabdominal neoplasms) and imaging findings (focal
alteration in the context of a healthy artery, signs of
inflammation in the periphery of the lesion, marked aneurysm
wall irregularities).
Procedure Technique
Prior to the interventional procedure, CT angiography was
performed to evaluate and confirm the diagnosis and viability
of the endovascular procedure. The CT study was done at the
first hospital with a 16-slice Philips MDT MX 8000 multide-
tector helical CT (Philips Healthcare, Cleveland, OH, USA) and
at the second center with a 64-slice multidetector helical CT,
the Siemens SOMATOM Sensation 64 (Siemens, Erlangen,
Germany). The acquired native images were assessed in a
workstation with multiplanar reconstructions and maximum
intensity projection. The measurements of the aneurysm and
afferent/efferent vessels were done with digital subtraction
angiography.
As an imaging guide for the treatment, 2 angiographic
devices were used: Digital Innova 2000 (GE, New York, NY,
USA) and Siemens AXIOM Artis (Siemens, Erlangen, Germany).
Depending on the hemodynamic situation of the patient,
the procedure was performed under local anesthesia and
sedation or general anesthesia (preferable in noncompliant
patients or in cases where intensive monitoring and treatment
were necessary during the procedure due to the hemodynamic
instability of the patient). Prior to stent placement, the
protocol required systemic heparinization to prevent throm-
boembolic complications (100 IU/kg up to a maximum of
5000 IU). If the procedure lasted for more than 60 min after the
initial bolus, a second bolus of 1000 IU sodium heparin was
administered every hour. In cases of bleeding secondary to
aneurysm or pseudoaneurysm, according to the clinical
situation of the patient, the risk of heparinization was
assessed. In no case with correct excision of the lesion was
it considered necessary to reverse heparin to decrease the risk
of acute stent occlusion. All patients received a broad-
spectrum antibiotic prior to the procedure to prevent
infections due to possible stent contamination or infections
secondary to necrotic tissue in case of distal organ infarction.CIRENG-1767; No. of Pages 10
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established for 30–60 days (clopidogrel 75 mg/day and AAS
100 mg/day), and mono-antiplatelet therapy was maintained
with AAS 100 mg/day, indefinitely. According to the location of
the lesion, different vascular accesses (femoral, axillary or
humeral) were used to minimize technical difficulties for
accessing the affected artery. Guiding catheters (6 F) or long
introducer sheaths (6 to 9 Fr) were used to introduce the stent to
the release site and avoid displacement. Six different types of
self-expanding and balloon-expandable coated prostheses
were used: Jostent Grafmaster (Abbott Vascular, Rangendin-
gen, Germany), Jomed (Jomed International AB, Helsingborg,
Sweden), Symbiot (Boston Scientific, Natick, MA, USA), Advanta
(Atrium Medical Corporation, Hudson, NH, USA), Viabhan (WL
Gore, Flagstaff, AZ, USA) and Be-Graft (Bentley Innomed GmbH,
Hechingen, Germany). In some cases, if the lesion was not
correctly sealed due to the stent length, more than one stent
was placed telescopically or in different branches (in cases of
vascular division) with the intention of maintaining the
permeability of all divisions. In the presence of collateral
branches originating in the aneurysm, previous coil emboli-
zation was performed to avoid type II endoleaks.
During the procedure, safety variables included complica-
tions related with the arterial puncture site (arterial perfora-
tion/dissection), rupture of the aneurysm/pseudoaneurysm,
stent migration or acute thrombosis, ischemic damage to the
distal organ, and death. Intraprocedural complications were
classified as minor or major according to the Society of
Interventional Radiology (SIR) classification30,31 (Table 1).
The technique was considered a success when the stents
were correctly placed in the planned location. The procedure
was considered effective when stent placement in the planned
situation demonstrated the following characteristics: no
endoleak, stent permeability and exclusion of the circulatory
aneurysm.
Patient follow-up entailed clinical and radiological evalua-
tion using CT angiography, MR angiography or color Doppler
plus CT angiography. Long-term effectiveness in the clinical-
radiological follow-up was defined as: exclusion of the
aneurysm from circulation, with absence of endoleak and
with a permeable stent. Long-term safety was also assessed by
collecting the following variables: emergence of new
symptoms, stent migration or thrombosis, ischemic damage
to the distal organ, and 30-day mortality related to the
procedure.Table 1 – SIR Grading System for Complications Accord-
ing to Prognosis.
Minor complications
A. No treatment or consequences
B. Maintenance therapy, with no consequences; one night of
observation
Major complications
C. Requires treatment, minor hospitalization (48 h)
D. Requires major treatment, unplanned increase in level of care,
prolonged hospitalization (48 h)
E. Permanent sequelae
F. DeathStatistical Analysis
We performed a descriptive statistical study that included the
frequencies and percentages for categorical variables and the
mean, standard deviation and median (interquartile range) for
the continuous variables. The analysis was performed with
the SPSS version 20.0 statistical package (SPSS, Chicago, IL,
USA).
Results
Twenty-five patients (16 men and 9 women) were identified
with 25 lesions diagnosed as visceral aneurysms (n=19) or
visceral pseudoaneurysms (n=6), with a mean age of 59 years
(range 27–79). To treat the 25 lesions, a total of 29 stents were
placed. The location of the lesions was: splenic artery (n=12),
hepatic artery (n=5), renal artery (n=4), celiac artery (n=3) and
gastroduodenal artery (n=1). Table 2 summarizes the patient
data (patients 1, 2 and 3 have already been reported in another
series).22
Out of the 19 aneurysms, 16 were incidentally detected and
3 presented abdominal pain (one of which was hemorrhaging
at the time of diagnosis). The 6 pseudoaneurysms had
hemorrhage or abdominal pain. All pseudoaneurysms and
aneurysms that were symptomatic or larger than 5 cm were
considered urgent.
The procedure was technically successful in 24 patients
(27 of the 29 stents), with no endoleak in the immediate
postoperative follow-up and adequate stent permeability.
The efficacy rate was 96%, with immediate exclusion of the
aneurysm in 24 of the 25 cases, as verified in the final
angiographic series (Fig. 1). In one case with a common celiac
artery/hepatic artery aneurysm, 2 stents were placed in
parallel: one from the common trunk to the splenic artery
and the other from the common trunk to the left gastric
artery. The procedure was completed with coil embolization
of the hepatic artery distal to the aneurysm and proximal to
the gastroduodenal artery, preserving the distal hepatic flow
and excluding the aneurysm from circulation. In another 4
cases, prior to stent placement, collateral branches origina-
ting at the aneurysm were embolized to avoid type II
endoleaks. In 3 patients, 2 stents were placed telescopically.
One of these cases, a splenic artery aneurysm, was the
patient in whom the procedure could not be completed (upon
placing the second stent, there was poor positioning of the
distal end and it fell into the aneurysmal sac. In the
arteriography series, extravasation of contrast medium
was observed, so it was decided to embolize the aneurysm
and the proximal artery with coils; the aneurysm was
correctly excluded, although the patient presented compli-
cated splenic ischemia with an abscess). In addition to this
intra-procedural major complication (type C), another 2
minor complications (type B) were detected related with the
arterial puncture site: 2 pseudoaneurysms (one femoral and
one axillary), which were both controlled with manual
compression and without the need for transfusion or other
supportive measures. The overall percentage of complica-
tions was 12% (3/25), 4% of which (1/25) were major
complications and 8% (2/25) were minor.CIRENG-1767; No. of Pages 10
Table 2 – Summary of Patients Treated in Our Series.
Patient Age/
Sex
Size
(cm)
Type Location Stent: n/Type/
Size in mm
Embolization
of collaterals
Complications Follow-up
(months)
Follow-up
(complications)
1 76/M 3.5 Aneurysm Splenic 1/Jostent G Ma´ster/526 No No 20 No
2 55/H 3.2 Aneurysm Splenic 1/Jomed/538 No No 28 No
3 67/M 3 Aneurysm Splenic 1/Advanta/759 No No 20 No
4 69/H 2.7 Aneurysm Hepatic 1/Jomed/538 No No 24 No
5 65/H 3 PseudoA. G.duodenal 1/Jomed/538 Yes No 20 No
6 78/M 2.2 Aneurysm Splenic 1/Symbiot/545 No No 24 No
7 52/M 2.3 Aneurysm Splenic 1/Symbiot/531 No No 36 Occlusion and migration
8 75/H 6 Aneurysm Splenic 2/Viabahn/650 No Yes (major) No –
9 63/H 4 PseudoA. Hepatic 1/Viabahn/850 No No 72 No
10 27/H 2.5 Aneurysm Renal 1/Jomed/519 No No 25 No
11 58/M 2.2 Aneurysm Renal 1/Jostent G Ma´ster/526 No No 72 Endoleak (spontaneous resolution)
12 69/M 2.3 Aneurysm Splenic 1/Viabahn/650 No Yes (minor) 72 No
13 61/H 0.9 PseudoA. Hepatic 1/Advanta/538 No No 24 Occlusion
14 73/M 6 PseudoA. Splenic 1/Viabahn/550 No No 46 Occlusion and migration
15 50/M 2.4 Aneurysm Splenic 1/Be Graft/538 No No 24 No
16 40/H 3.8 Aneurysm Splenic 1/Viabahn/650 No No 36 No
17 44/H 3.5 Aneurysm Splenic 1/Advanta/649 No No 28 No
18 50/H 3.3 Aneurysm Splenic 1/Viabahn/650 No No 72 No
19 64/H 5 PseudoA. Hepatic 2/Advanta/622–638 No No 36 No
20 55/H 4.3 PseudoA. Hepatic 1/Advanta/622 No Yes (minor) 6 No
21 34/H 2.2 Aneurysm Celiac trunk 1/Viabahn/750 Yes No 17 No
22 63/H 2.4 Aneurysm Renal 2/Advanta/622 No No 6 No
23 46/M 4 Aneurysm Trunk/Hepatic 2/Advanta/638 (2 arteries) Yes No 36 Occlusion (only 1)
24 70/H 2.2 Aneurysm Renal 1/Viabahn/1050 No No 8 No
25 79/H 4.5 Aneurysm Trunk/Splenic 1/Advanta/839 Yes No 30 Endoleak (spontaneous resolution)
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Fig. 1 – Pseudoaneurysm of the hepatic artery measuring 4 cm, treated with coated stent placement (Viabahn 8T50 mm):
(A and B) CT angiogram prior to treatment; (C) selective angiogram from the superior mesenteric artery, where
repermeabilization is observed of the hepatic artery proper through the gastroduodenal artery; (D) rotational angiography
done from the celiac trunk; (E–F) placement and angiographic follow-up after positioning the stent, which shows complete
exclusion of the pseudoaneurysm with permeability; (G) CT angiogram 72 months after the procedure, showing evidence of
stent permeability and absence of endoleaks.
c i r e s p . 2 0 1 7 ; x x ( x x ) : x x x – x x x6In our series, we did not detect dissection, rupture of the
aneurysm/pseudoaneurysm, thrombosis or stent migration
during the procedure. There was also no intraprocedural
mortality. The mean hospitalization time in the true
aneurysms was 40 h, while in pseudoaneurysms it was 7 days.In the 24 patients with coated stent placement, clinical/
radiological follow-up was an average of 33 months long
(range 6–72 months). Radiological testing showed adequate
aneurysm exclusion in all cases, although stent occlusion was
detected in 4 patients (long-term efficacy 86%). The patientCIRENG-1767; No. of Pages 10
c i r e s p . 2 0 1 7 ; x x ( x x ) : x x x – x x x 7with intraprocedural type C complication and coil emboliza-
tion was excluded from follow-up to assess long-term efficacy.
Radiological follow-up included CT angiogram in 20 patients
and CT angiogram plus color Doppler ultrasound in 2 patients.
In the remaining 2 patients, MR angiography was used because
of their age (27 and 34 years).
During follow-up, 2 endoleaks were found, one after one
month and one after 6 months. These endoleaks had no
repercussions on the size of the aneurysmal sac and did not
require any additional intervention, resolving spontaneously
after 6 and 24 months, respectively. Out of the 4 patients who
underwent prophylactic embolization to prevent type II
endoleak, 3 had no endoleak in successive controls and the
fourth was described previously with endoleak after one
month that resolved spontaneously after 6 months. Deferred
complications included 4 stent thromboses (4/24; 16%): one
after 1 month in a pseudoaneurysm of the hepatic artery, one
after 3 months in a pseudoaneurysm of the splenic artery and
2 after 6 months (one in a splenic aneurysm and another in a
celiac artery aneurysm). In none of the cases was evidence
found of any clinical symptoms or ischemic injury to the
related organ.
In the 2 patients with thrombosis of the stent placed in
the splenic artery, migration occurred (2/24; 8%). In one, the
migration was proximal, probably because of an incorrect
measurement due to overestimation of the treated artery,
although there were no clinical repercussions or recanalization
of the aneurysm. In the second case, a perforation of the gastric
wall occurred 36 months after its placement. In the latter case,
due to the oncological comorbidities of this patient resulting in
a short life expectancy, the approach was noninvasive. The
patient died 10 months later due to this baseline disease:
adenocarcinoma of the head of the pancreas. This case was has
already been reported in the literature.21
Discussion
Surgery is still the treatment of choice in patients with visceral
aneurysms and pseudoaneurysms because in many instances
it allows the surgeon to treat the vascular lesion and its cause in
the same operation. In the last 10 years, however, interventio-
nal radiology has offered several treatment alternatives in
aneurysmal and pseudoaneurysmal vascular lesions, with a
general decrease in hospitalization times compared to con-
ventional surgery and a mortality rate ranging from 0 to
10.5%.9,12,15,32–34 This is largely due to the fact that these
techniques are minimally invasive and can be performed with
local anesthesia and sedation, which makes their application
possible in patients with high anesthesia risk. This fact is
supported by the results of our series, in which we had a
mortality of 0%. In our experience, the coated stent treatment
had a technical success rate of 96%, with immediate efficacy of
100% and long-term efficacy of 86% in those patients with
technical success. If we did not consider stent permeability as
part of the efficacy variable (as in the case of embolization with
plugs and coils) and only considered the exclusion of bleeding,
the long-term efficacy would continue to be 100%.
The complication rate during the procedure was 12% (4%
major, 8% minor). In the follow-up, complete occlusion of theaneurysm was confirmed in all cases, with a stent thrombosis
rate of 16% (there was no ischemic organ injury in any of these
patients), and the migration rate was 8%.
In our series, no deaths occurred due to the procedure. In
the literature, the technical success of endovascular treatment
including all techniques (coils, stents and coils, coated stents,
etc.) was between 57.1% and 100%,12,13,29,32,35 depending on
several factors, including: the morphology of the afferent/
efferent vessels and the aneurysm itself; aneurysm location;
presence of associated disease; and, operator experience. Our
results, with a technical success of 96%, would fall within this
range.
It should be noted that, as the technology used in
interventional radiology has evolved, there has also been an
improvement in the clinical results obtained in the procedures.
Table 3 summarizes the main series of the literature that deal
with the endovascular technique in comparison with ours. In a
comparative study by Shukla et al.,4 the endovascular
technique and conventional surgery did not present significant
differences in terms of major periprocedural complications and
30-day mortality in the treatment of unruptured aneurysms. In
the case of ruptured aneurysms, several studies have demons-
trated lower morbidity and mortality in patients treated by the
endovascular approach.4,36,37 It is important to emphasize the
importance of patient selection for endovascular treatment to
achieve adequate exclusion of the aneurysm with permeability
of all the visceral arteries. Otherwise, there is a potential for
severe ischemic damage and the surgical technique should be
the treatment of choice. Likewise, it should be taken into
account that patients treated with the endovascular method
need retreatment more frequently than patients treated
surgically. In patients with ruptured aneurysms, the retreat-
ment rate in endovascular treatment is 15% compared to 8.2%
of patients treated surgically, although these differences are
not statistically significant.4
The overall complication rate of 12% detected in our series
is within the range of complication rates for the endovascular
technique generally reported in other series (0%–50%).9,29,38–41
According to a recently published meta-analysis,12 the
literature reports a rate of endoleaks-recanalization, including
the different techniques, of 5.4% (ranging from 0% to 26% in
cases of coiling with long-term follow-up).32,41,42 The need for
retreatment ranges between 0 and 15%.4,13,34,35 In our
experience, we had 2 cases of endoleaks during follow-up,
which, due to the absence of increased size or symptoms, did
not require treatment. In fact, in both cases spontaneous
resolution was observed in the radiological follow-up with CT
angiography at 6 and 24 months. In the follow-up of these
patients, we had 4 cases of thrombosis after 1, 6 and 12
months, with no evidence of ischemic injury to the associated
organ. Kunzle et al. also reported 2 cases of asymptomatic
thrombosis during follow-up.28 Acute thrombosis was not
reported in this series or in our series. Late thrombosis seems
to be better tolerated thanks to collateral hemodynamic
compensation, thereby avoiding ischemic damage to the
affected organ. This is unlike coil embolization, in which
acute and voluntary occlusion of the treated vessel may cause
relevant ischemic injury.
In our series, in the case of technical failure, the splenic
artery had to be embolized with coils, which causedCIRENG-1767; No. of Pages 10
Table 3 – Studies About Endovascular Treatment of Visceral Aneurysms and Pseudoaneurysms.
Article Technique Treatments
(n)
Therapeutic
success n (%)
Mortality
n (%)
Complications
n (%)
Kunzle et al. (28) Coated stent 19 16 (84.2) 1 (5.3) 1 (5.3)
Zhang et al.29 Coated stent 10 10 (100) 0 (0) 0 (0)
Pitton et al.11 Coils, Coated stent, NBCA, vascular plug 45 42 (93.3) 2 (4.4) 5 (11.1)
Yasumoto et al.32 Coils 46 46 (100) 0 (0) 7 (15.2)
Guo et al.15 Coils, stent, Coated stent 113 110 (97.3) 3 (2.6) 24 (21.2)
Dorigo et al.34 Coils, Coated stent, MFM 26 23 (89) 0 (0) 2 (7.7)
Tulsyan et al.9 Coils, stent, NBCA 48 47 (98) 1 (2.0) 11 (22.9)
Patel et al.39 Coils, gelfoam 63 62 (98) NP 21 (40)
Spiliopoulos et al.48 Coils, Coated stent, vascular plug 58 58 (100) 0 (0) 5 (8.6)
Lagana et al.42 Coils, Coated stent, NBCA, thrombin 29 26 (89.7) 0 (0) 8 (27.5)
Balderi et al.49 Coils, Coated stent, MFM, vascular plug 31 31 (100) 1 (3.2) 8 (25.8)
Won et al.50 Coils, NBCA 14 14 (100) 0 (0) 2 (14.2)
Sachdev et al.41 Coils, Coated stent 35 31 (89) 0 (0) 9 (31.0)
Etezadi et al.51 Coils, stent, Coated stent, gelfoam, thrombin,
particles, plug vascular plug
41 40 (98) 0 (0) 7 (17.0)
Nicholson et al.33 Coils, Coated stent 19 17 (89.5) 2 (10.5) NP
Ferrero et al.40 Coils, Coated stent, MFM, NBCA, thrombin 8 NP 0 (0) 4 (50.0)
Saeed et al.38 Coils, vascular plug 8 8 (100) NP 0 (0)
Cochennec et al.35 Coils, Coated stent, Onyx 15 15 (100) 0 (0) 1 (6.6)
Chiesa et al.13 Coils 7 4 (57.1) 0 (0) 14.3
Vallina-Victorero et al.52 Coils, stent 4 4 (100) 0 (0) 1 (25.0)
Gehlen et al.45 Coils 3 2 (67) 0 (0) 0 (0)
Kok et al.12 Coils, thrombin, NBCA, MFM 19 19 (100) 0 (0) 3 (15.7)
Bratby et al.53 Onyx 3 3 (100) 0 (0) 0 (0)
Our series Coated stent 25 24 (96) 0 (0) 3 (12)
Gelfoam: Pfizer, Puurs, Belgium; NBCA: N-butyl cyanoacrylate; NP: not published; Onyx: Covidien, Irvine, CA, USA; MFM: multilayer flow
modulator stent; Tx: treatments.
c i r e s p . 2 0 1 7 ; x x ( x x ) : x x x – x x x8complicated ischemia with a splenic abscess. Similarly in our
series, thrombosis was associated with stent migration in 2
cases, one asymptomatic and one with fistulization to the
stomach. In the literature, stent migration into splanchnic
vessels usually occurs in association with the placement of
EVAR, which are always intravascular migrations. In contrast,
extravascular migrations are extremely rare events that
appear to be due to the cytotoxic effects of chemotherapy43
or chronic local inflammatory conditions like pancreatitis, as
in our case. In a mixed surgical and endovascular series,
Ferrero et al. report one case of coated stent migration in a
patient with a celiac trunk aneurysm and previous aorto-
aortic bypass; the case was resolved with placement of a
second stent.40
In the published series, embolization with platinum coils is
the most commonly used technique.12 But, since it does not
guarantee the distal permeability to the embolized vessel area,
different complications related to this technique have been
reported, such as sac perforation,1 postembolization
syndrome (0%–30% of cases)9,29,35,44 and major ischemia of
organs vascularized by said arteries (50% or more of the organ),
which, according to the literature, can occur in 0 to 21% of
cases.32,39,45 From a theoretical standpoint, which our expe-
rience endorses, the endovascular technique that would
reduce the rate of this type of complications is the use of
coated stents, since they preserve the permeability of the
treated vessel (with a lower associated risk of perforation of
the aneurysmal sac and distal embolus)46 while reducing the
time of the procedure.29,45 Stent repair of aneurysms and
pseudoaneurysms is particularly indicated in cases of wide
neck aneurysms (2:1 ratio between the diameter of theaneurysm and the neck), situated in vessels proximal to the
aorta or those with limited tortuosity (given the limitation of
the profile of current stents that require a minimum size of 6
Fr), both electively and urgently. Similar to most groups, our
preference is the use of balloon-expandable stents in cases
where high precision is required when placing the device
(non-embolizable branches near the sac, aneurysms very
proximal to the aorta) and in areas where there is no risk of
extrinsic compression. We prefer self-expandable stents in
cases where greater flexibility of the device is more useful due
to the tortuosity of the affected vessels. It is also important to
remember that, in addition to various brands of stents, there
are also differences in lengths, which should be considered
when deciding on the device to be used.
Preventive embolization of collateral branches at the origin
of the aneurysm is recommended to avoid endoleaks; the coil
technique is the most widely used. Kunzle et al.28 reported one
case of organ infarction out of 9 embolizations. In our series,
embolization of the collateral branches was necessary in 4
cases, with no evidence of related ischemic damage. In
another series of 10 patients, treated only with coated stents
and limited to patients with celiac trunk aneurysm, the
authors reported a 100% success rate without complications.29
The use of multilayer stents with flow redirection could be
an alternative to the use of coated stents, with the potential
advantage of the preservation of collateral branches. There are
still few data in the literature concerning the use of multilayer
stents, and these are limited to elective cases. One of the most
extensive series is that of Ruffino et al. on 19 aneurysms
treated with the Cardiatis Multilayer Flow Modulator stent
(Cardiatis, Isnes, Belgium), which, after 6 months, presentedCIRENG-1767; No. of Pages 10
c i r e s p . 2 0 1 7 ; x x ( x x ) : x x x – x x x 9aneurysm exclusion in 87.5% of the cases, with collateral
preservation in all cases. Stent thrombosis occurred in 2
cases.47
Ours is the first multicenter study and the most numerous
series published in the literature about the endovascular
treatment of visceral aneurysms with coated stents. The study
presents some limitations: it is retrospective, the number of
patients is insufficient to perform a statistically significant
analysis, and adequate stratification is not possible (due to the
extreme variability of the characteristics of the aneurysm, the
vessel involved and the type of stent used). Last of all, there are
currently no clinical practice guidelines available for the
treatment or follow-up of this condition.
In our study, the endovascular treatment of visceral
aneurysms and pseudoaneurysms using coated stents was
found to be safe and effective, in both elective and emergency
situations, with a high rate of therapeutic success and a low
rate of long-term complications.
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